Now I'm interested.In a small single-centre, double-blind, placebo-controlled clinical pilot study, an experimental Pleneva™ prototype provided clinical benefits to patients with RRMS, including decreases in both relapse rate and EDSS scores, with additional benefits seen on pain and cognitive endpoints.
scoobyjude wrote:BTG Commences Phase IIa Study Of Pleneva For Multiple Sclerosis - Quick Facts
1/21/2010 2:51 AM ET
(RTTNews) - BTG Plc (BGC.L: News ) said it commenced dosing in a European multicentre Phase IIa study of Pleneva, a novel orally administered compound under development as a potential treatment for multiple sclerosis.
According to the company, the study, in 166 patients with the relapsing-remitting form of the disease, comprises an initial 24 week double-blind, placebo-controlled dosing period followed by a 24 week open-label extension. The primary endpoint of the study is a reduction in the number of new T1 gadolinium enhanced lesions on MRI at weeks 12, 16, 20 and 24 when compared to placebo.
arabia wrote:any update ? please
Users browsing this forum: Scott1